Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. - Wikidata - awgldk - TriplyDB

Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever.

Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever.

http://www.wikidata.org/entity/Q34257290

about

Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques Ebola virus disease and critical illness.Filoviruses: One of These Things is (not) Like the Other Mouse models for filovirus infections Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection Discovery of an antibody for pan-ebolavirus therapy Ebola management centre proximity associated with reduced delays of healthcare of Ebola Virus Disease (EVD) patients, Tonkolili, Sierra Leone, 2014-15.Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.An update on the use of antibodies against the filoviruses.Structures of protective antibodies reveal sites of vulnerability on Ebola virus.Immune memory to Sudan virus: comparison between two separate disease outbreaks.Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy.Structural basis for Marburg virus neutralization by a cross-reactive human antibody.Mechanism of human antibody-mediated neutralization of Marburg virus High Inter-Individual Diversity of Point Mutations, Insertions, and Deletions in Human Influenza Virus Nucleoprotein-Specific Memory B Cells Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.Natural Immunity to Ebola Virus in the Syrian Hamster Requires Antibody Responses Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies.Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay.Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material.Potential vaccines and post-exposure treatments for filovirus infections.Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections.Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates Potent neutralizing monoclonal antibodies against Ebola virus infection Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site Antibody therapy for Ebola: is the tide turning around?Antibody therapeutics for Ebola virus disease.Novel mutations in Marburg virus glycoprotein associated with viral evasion from antibody mediated immune pressure.Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus.Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.Characterization of host immune responses in Ebola virus infections.

P2860

Q24594601-A2511849-4BC7-4C69-86C8-E7CFB3A21E8F Q24612811-2D59F624-5F59-4673-B31C-B1B611DB5307 Q26250274-89917DB9-7A20-4D84-BD2E-4B26F18E1383 Q26783063-6156B79E-BC67-4E2C-8CEE-CA50565AA6AD Q27011569-F900372A-468B-451C-A1D5-C68E63281C6F Q27324824-842CB2C7-9891-45FB-BD5E-EA008186CDCE Q30385927-55200899-9AA4-48A9-AAFA-891FD84172CB Q33620801-F9981FCF-864C-4912-A076-4EA1C14B066C Q33733844-F10D818B-5FA9-45E8-B50F-54021CBC4F95 Q34361120-C81B0A23-9D74-494C-B9A6-1F0822733D27 Q34463780-6F3A475C-50F8-4FA6-8729-82AE62098A43 Q34657170-98843DC8-ED38-4C43-B118-480AC817F0BC Q34661120-19ACE9D7-709E-4D8B-B201-882781C2E4A3 Q35014908-E8E82B32-9A8B-45DD-8DAD-3BA167B35F4C Q35107644-E6463859-7EA3-421E-AAA5-5E97820E7BB3 Q35132751-712952C9-D426-4CE4-8B81-BECAA0B19684 Q35132756-2CF179F8-2DE7-4F03-A10C-2755B189833E Q35666908-89B9AC99-4A5C-4BED-8562-BEF12CCB9AC7 Q35675647-C2CC9D73-8A14-4F8E-A273-2F493086C85B Q35793699-0DB953E4-336F-47EF-863B-F7C86C43988C Q36043254-5CD47608-4934-4F29-B7EA-4E59ACAA3007 Q36043290-F258CB37-B2C3-4D25-B159-C1DEB023F7E3 Q36208191-B1546C0C-4D36-4673-A171-FEDD3187CC9A Q36255716-A6AE5E28-C009-4C67-87B2-993B067F8EB9 Q36378625-7A3D3A29-5D57-4F11-A07E-F3CBA3D4BAEB Q36403500-A9FC2B07-8616-4C86-8DE2-BA3DA68C7114 Q36404178-FE068E45-A8C0-4D75-9047-0C8499B98DCB Q36414333-5499A54B-94EC-442C-8717-CB25DDAAD408 Q36432717-F31A9F8B-101B-458A-A7E7-4AA51235A455 Q36433920-4FA279C7-E6BE-4225-A456-25BBC1D59EB9 Q36433965-BEF4A526-C480-43C1-8120-CD725B8C0B1C Q36583281-C5034271-46A2-413B-A6D4-EB63273AB15C Q36903111-565BFC53-C2A5-49B4-88CF-C1E900100F4D Q36913606-5205DD46-A943-4524-AE9D-8AB39B3F7390 Q36977744-1D413F4F-CF0E-4256-ABA1-44689CFA9594 Q36994087-224365D2-79AD-4267-A994-912CF5294D95 Q37007013-7F9F82D6-3D4A-4009-9661-73A0545D0301 Q37738447-189E6153-D613-4CD8-B14F-914C30A80BB2 Q38098075-259A9CF4-C3A1-4C20-A600-95FF01CB728F Q38205274-C9984441-C560-479E-AE4B-5D772E5CBDD5

P2860

Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever.

http://www.wikidata.org/entity/Q34257290

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Protective efficacy of neutral ...... el of Ebola hemorrhagic fever.

@ast

Protective efficacy of neutral ...... el of Ebola hemorrhagic fever.

@en

Protective efficacy of neutral ...... el of Ebola hemorrhagic fever.

@nl

type

label

Protective efficacy of neutral ...... el of Ebola hemorrhagic fever.

@ast

Protective efficacy of neutral ...... el of Ebola hemorrhagic fever.

@en

Protective efficacy of neutral ...... el of Ebola hemorrhagic fever.

@nl

prefLabel

Protective efficacy of neutral ...... el of Ebola hemorrhagic fever.

@ast

Protective efficacy of neutral ...... el of Ebola hemorrhagic fever.

@en

Protective efficacy of neutral ...... el of Ebola hemorrhagic fever.

@nl

P1433

Q34257290-7B180E11-79DC-4AE5-9382-47B7B931CD98

P1476

Q34257290-F1562149-89EF-4356-83D0-FCB065B5895E

P2093

Q34257290-4BDAD388-D8E7-4546-8418-EAA171549617

Q34257290-5AE9FF96-940E-47A3-BED9-2787445A8E23

Q34257290-66327DE1-CB16-4110-AA3A-35DAE2FA37F9

Q34257290-79652691-FBB4-4A0D-AA2D-9501FAF1BFC7

Q34257290-8C632D65-CFF6-4F3B-A9F9-70D233A7A837

Q34257290-A0EC6CB8-122F-4934-B6A5-A26616FD7D19

Q34257290-C3D7F0A3-59B2-4EAB-A229-83D1A2693B17

Q34257290-C7EB1BA0-8607-44FF-AC3E-28E0626F5298

Q34257290-E4CADA69-66F5-4DDB-BD83-7D6F6CBE7680

Q34257290-ED1E8D59-146F-41E8-A55A-697626A9980A

P2860

Q34257290-042EC9B2-74E4-4194-90BC-AA246E767D2E

Q34257290-049137AB-19C9-4FEF-A88A-A3235C51651D

Q34257290-096F562C-2036-4553-9179-7FE55D6D4DC7

Q34257290-17080775-BA20-4D62-8F76-B5DFA11BCD12

Q34257290-19480953-9DBE-4262-86B4-9E27EF9988E3

Q34257290-1FFD02BA-AB26-4E7F-9796-6FE1414AED67

Q34257290-2861E952-F8E8-4D4E-BBC1-F9DC84F82E8E

Q34257290-35CAC29F-1720-4E97-96B3-D8ECD1B35252

Q34257290-38389211-B76E-4829-87BC-284A79428AE8

Q34257290-3F3CECDB-18DF-4724-9148-B65CEC68CFC7

P304

Q34257290-E7210EC8-A160-45EC-9BE4-6092EA663C09

P31

Q34257290-FF203CED-5414-44CC-A541-6074F9FAC849

P356

Q34257290-80CB1124-EDED-4D84-9F0F-2D38537875EF

P407

Q34257290-68AB6988-6630-48C6-BBB3-DE88BAB5AD5B

P433

Q34257290-9AE4F777-3F89-4103-9324-53BA34C02B2F

P478

Q34257290-9C173467-27B5-4BD3-BB98-F669D9D43749

P50

Q34257290-346FF077-59C5-4654-A36E-5DC1AAA3AB66

Q34257290-A8BD34DB-71BF-409C-99C2-63321666AD23

Q34257290-DD4CEA93-B549-43C3-BF2B-832ABCFFF52C

Q34257290-DD85DFDB-F43D-47E9-A758-41B0A76CC747

Q34257290-FF193996-2C14-4160-A27E-E91D9DAECC5B

P577

Q34257290-A653770C-7A06-4FA5-8D59-A1CEB1517ED0

P5875

Q34257290-F3B883E7-1B95-4B7E-B610-35CB3C9904A8

P698

Q34257290-7C78BD6F-59EB-4B05-B4E9-E3FA3E1DF39B

P921

Q34257290-182B98FD-C959-4769-A807-45E2F0E627C4

Q34257290-97441B97-581B-41F3-B94C-72AFEFD07CB9

Q34257290-D2DF3499-43CE-4DE7-9A68-1390F402BF56

P932

Q34257290-61943344-287B-4E49-93BD-461945CCEAF1

P356

JOURNAL.PONE.0036192

P1433

P1476

Protective efficacy of neutral ...... el of Ebola hemorrhagic fever.

@en

P2093

Ayato Takada

http://www.w3.org/2001/XMLSchema#string

Douglas Brining

http://www.w3.org/2001/XMLSchema#string

Hiroko Miyamoto

http://www.w3.org/2001/XMLSchema#string

Makoto Kuroda

http://www.w3.org/2001/XMLSchema#string

Manabu Igarashi

http://www.w3.org/2001/XMLSchema#string

Mari Ishijima

http://www.w3.org/2001/XMLSchema#string

Megumi Higuchi

http://www.w3.org/2001/XMLSchema#string

Reiko Yoshida

http://www.w3.org/2001/XMLSchema#string

Yasuhiko Suzuki

http://www.w3.org/2001/XMLSchema#string

Yukie Matsuyama

http://www.w3.org/2001/XMLSchema#string

P2860

Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda

Ebola haemorrhagic fever

Antibody-dependent enhancement of Ebola virus infection

Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor

A shared structural solution for neutralizing ebolaviruses

Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs

Thoracic radiography as a refinement methodology for the study of H1N1 influenza in cynomologus macaques (Macaca fascicularis)

Ebola virus can be effectively neutralized by antibody produced in natural human infection.

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys

P304

e36192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0036192

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Friederike Feldmann

P577

2012-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224899605

http://www.w3.org/2001/XMLSchema#string

P698

22558378

http://www.w3.org/2001/XMLSchema#string

P921

Ebola virus disease

P932

3338609

http://www.w3.org/2001/XMLSchema#string